Chirag Shah, MD

Articles

66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

Pat W. Whitworth;Steven C. Shivers;Chirag Shah, MD;Rakesh Patel;Charles E. Cox, MS, FACS;Karuna Mittal;Troy Bremer

May 5th 2024

72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

Troy Bremer;Karuna Mittal;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balusubramanyam Karanam;Geza Acs;Elizabeth Pernicone;Melissa Tempest;Charles E. Cox, MS, FACS;Steven C. Shivers;Lotta Wadsten

April 13th 2024

38 Comparing Risk Stratification and Radiotherapy Benefit for Patients With DCIS Using a 7-Gene Biosignature as Compared to a Clinicopathologic Nomogram

Julie A. Margenthaler, MD;Karuna Mittal;Frank A. Vicini, MD;Chirag Shah, MD;Rachel Rabinovitch, MD;Pat W. Whitworth;Brian Czerniecki;David J. Dabbs;G. Bruce Mann;Fredrik Wärnberg;Sheila Weinmann;Michael Leo;Steven C. Shivers;Troy Bremer

April 26th 2023

39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

Rachel Rabinovitch, MD;Frank A. Vicini, MD;Chirag Shah, MD;Julie A. Margenthaler, MD;Brian Czerniecki;Pat W. Whitworth;David J. Dabbs;G. Bruce Mann;Fredrik Wärnberg;Sheila Weinmann;Michael Leo;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer

April 26th 2023

40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

Frank A. Vicini, MD;Chirag Shah, MD;Rachel Rabinovitch, MD;Pat W. Whitworth;Julie A. Margenthaler, MD;Brian Czerniecki;David J. Dabbs;Sheila Weinmann;Michael Leo;G. Bruce Mann;Fredrik Wärnberg;Jess Savala;Steven C. Shivers;Karuna Mittal;Troy Bremer

April 26th 2023

41 Changes in Treatment Recommendation for Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

Pat W. Whitworth;Steven C. Shivers;Chirag Shah, MD;Rakesh Patel;Karuna Mittal;Troy Bremer;Charles E. Cox, MS, FACS

April 26th 2023

37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

Steven C. Shivers;Pat W. Whitworth;Rachel Rabinovitch, MD;Frank Vicini, MD;Chirag Shah, MD;Fredrik Wärnberg;G. Bruce Mann;Karuna Mittal;Troy Bremer

May 6th 2022

38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

Pat W. Whitworth;Rachel Rabinovitch, MD;Frank A. Vicini, MD;Chirag Shah, MD;Fredrik Wärnberg;G. Bruce Mann;Steven C. Shivers;Karuna Mittal;Troy Bremer

May 6th 2022

POINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?

Camille Berriochoa, MD;Carisa Bohnak, BS;Nicole Chahine, BS;Chirag Shah, MD

August 15th 2017

At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences.

Accelerated Partial-Breast Irradiation: Does the Evidence Stack Up?

Chirag Shah, MD;Shahed Badiyan, MD;Shariq Khwaja, MD, PhD;Frank Vicini, MD

April 15th 2013

APBI is a technique that offers women with early-stage breast cancer a choice. The preponderance of evidence supports the efficacy and safety of this technique, and it should continue to be offered to appropriately selected patients on and off protocol.

Granulocytic Sarcoma in a Patient With Myelodysplastic Syndrome

Chirag Shah, MD;Srivalli Gopaluni, MD;Juhi Husain, MD;Arun Rajan, MD

July 1st 2008

Our case illustrates the fact that MDS-associated GS can be treated palliatively with radiation and hypomethylating agents in an appropriate setting. With the growing geriatric patient population, effective treatment options are needed in this disease.